Lion Street Advisors LLC Purchases 21 Shares of Eli Lilly and Company $LLY

Lion Street Advisors LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 4.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 531 shares of the company’s stock after purchasing an additional 21 shares during the period. Lion Street Advisors LLC’s holdings in Eli Lilly and Company were worth $414,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in LLY. WestEnd Advisors LLC raised its position in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after acquiring an additional 21 shares during the period. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $27,000. Citizens National Bank Trust Department raised its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. bought a new stake in shares of Eli Lilly and Company in the first quarter valued at approximately $40,000. Finally, TD Capital Management LLC raised its position in shares of Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after purchasing an additional 31 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $818.60 on Tuesday. The firm has a market capitalization of $774.77 billion, a price-to-earnings ratio of 53.50, a P/E/G ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $937.00. The stock has a fifty day moving average of $743.43 and a 200 day moving average of $765.54. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO David A. Ricks purchased 1,632 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director J Erik Fyrwald purchased 1,565 shares of the business’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Deutsche Bank Aktiengesellschaft lowered their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $948.06.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.